Adenomyosis is frequently observed in premenopausal women, and oral dienogest is the recommended treatment to target the underlying pathology and improve the symptoms. This retrospective study investigated the association of Lewis (b) antigen expression with outcomes of dienogest therapy among women with adenomyosis. Records from a total of 342 adenomyosis patients were analysed, who were prescribed with oral dienogest for a maximum of 16 weeks. Expression levels of Lewis (b) antigen were measured to categorize all patients into either Le (b)- and Le(b)+ groups. Treatment outcomes, in terms of uterine volume, menstrual flow, pain symptoms and quality of life, were compared between the two groups. While oral dienogest therapy showed considerable clinical efficacy in both groups of patients, the extent of improvements in treatment outcomes was significantly more pronounced in Le (b)- group than Le (b)+ group, with respect to treatment time, uterine symptoms, menstrual flow, pain symptoms and quality of life. No difference in adverse effects was observed between the two groups. Expression of Lewis (b) blood group antigen interferes with oral dialogist therapy among women with adenomyosis.

中文翻译：

---

Lewis（b）血型抗原的表达会干扰子宫腺肌病女性的口服去头孕疗法。

绝经前女性经常观察到子宫腺肌病，建议采用口服去头孕激素来针对潜在的病理学并改善症状。这项回顾性研究调查了患有子宫腺肌病的女性中Lewis（b）抗原表达与去死孕疗法结局的关系。分析了来自总共342名子宫腺肌病患者的记录，这些患者被处方口服口臭，最长不超过16周。测量Lewis（b）抗原的表达水平，将所有患者分为Le（b）-和Le（b）+组。比较两组的子宫体积，月经量，疼痛症状和生活质量等治疗结果。口服去死孕疗法在两组患者中均显示出可观的临床疗效，就治疗时间，子宫症状，月经量，疼痛症状和生活质量而言，Le（b）-组的治疗结局改善程度明显高于Le（b）+组。两组之间未观察到不良反应的差异。Lewis（b）血型抗原的表达会干扰子宫腺肌病女性的口服对话疗法。